0000899243-23-011461.txt : 20230419 0000899243-23-011461.hdr.sgml : 20230419 20230419194513 ACCESSION NUMBER: 0000899243-23-011461 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230417 FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yeramian Patrick D CENTRAL INDEX KEY: 0001358266 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 23831112 MAIL ADDRESS: STREET 1: 1815 PARKSIDE CIRCLE SOUTH CITY: BOCA RATON STATE: FL ZIP: 33486 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-17 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001358266 Yeramian Patrick D C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 0 1 0 0 Chief Medical Officer 1 Common Stock 2023-04-17 4 M 0 44861 0.37 A 253278 D Common Stock 2023-04-17 4 M 0 4718 6.88 A 257996 D Common Stock 2023-04-17 4 S 0 49279 30.5335 D 208717 D Common Stock 2023-04-17 4 S 0 300 30.94 D 208417 D Stock Option (right to buy) 0.37 2023-04-17 4 M 0 44861 0.00 D 2029-03-18 Common Stock 44861 17605 D Stock Option (right to buy) 6.88 2023-04-17 4 M 0 4718 0.00 D 2031-02-21 Common Stock 4718 43534 D These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023. As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023. /s/ Joshua B. Cohen, as Attorney in Fact 2023-04-19